{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T06:13:50Z","timestamp":1772172830007,"version":"3.50.1"},"update-to":[{"DOI":"10.1371\/journal.pcbi.1008728","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T00:00:00Z","timestamp":1615334400000}}],"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:00:00Z","timestamp":1614297600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003006","name":"ETH Z\u00fcrich","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003006","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Botnar Research Centre for Child Health","award":["2020-FS-354"],"award-info":[{"award-number":["2020-FS-354"]}]}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"abstract":"<jats:p>\n                    Large-scale serological testing in the population is essential to determine the true extent of the current SARS-CoV-2 pandemic. Serological tests measure antibody responses against pathogens and use predefined cutoff levels that dichotomize the quantitative test measures into sero-positives and negatives and use this as a proxy for past infection. With the imperfect assays that are currently available to test for past SARS-CoV-2 infection, the fraction of seropositive individuals in serosurveys is a biased estimator of the cumulative incidence and is usually corrected to account for the sensitivity and specificity. Here we use an inference method\u2014referred to as\n                    <jats:italic>mixture-model approach<\/jats:italic>\n                    \u2014for the estimation of the cumulative incidence that does not require to define cutoffs by integrating the quantitative test measures directly into the statistical inference procedure. We confirm that the mixture model outperforms the methods based on cutoffs, leading to less bias and error in estimates of the cumulative incidence. We illustrate how the mixture model can be used to optimize the design of serosurveys with imperfect serological tests. We also provide guidance on the number of control and case sera that are required to quantify the test\u2019s ambiguity sufficiently to enable the reliable estimation of the cumulative incidence. Lastly, we show how this approach can be used to estimate the cumulative incidence of classes of infections with an unknown distribution of quantitative test measures. This is a very promising application of the mixture-model approach that could identify the elusive fraction of asymptomatic SARS-CoV-2 infections. An R-package implementing the inference methods used in this paper is provided. Our study advocates using serological tests without cutoffs, especially if they are used to determine parameters characterizing populations rather than individuals. This approach circumvents some of the shortcomings of cutoff-based methods at exactly the low cumulative incidence levels and test accuracies that we are currently facing in SARS-CoV-2 serosurveys.\n                  <\/jats:p>","DOI":"10.1371\/journal.pcbi.1008728","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T13:44:34Z","timestamp":1614347074000},"page":"e1008728","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":21,"title":["Estimating the cumulative incidence of SARS-CoV-2 with imperfect serological tests: Exploiting cutoff-free approaches"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3781-0675","authenticated-orcid":true,"given":"Judith A.","family":"Bouman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3808-2852","authenticated-orcid":true,"given":"Julien","family":"Riou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8052-3925","authenticated-orcid":true,"given":"Sebastian","family":"Bonhoeffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8319-5293","authenticated-orcid":true,"given":"Roland R.","family":"Regoes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,2,26]]},"reference":[{"key":"pcbi.1008728.ref001","unstructured":"Johns Hopkins Center for Health Security. Global Progress on COVID-19 Serology-Based Testing Johns Hopkins Center for Health Security. 2020 Apr 13. URL: http:\/\/www.centerforhealthsecurity.org\/resources\/COVID-19\/serology\/Serology-based-tests-for-COVID-19.html."},{"issue":"12","key":"pcbi.1008728.ref002","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1007\/s10096-020-03978-6","article-title":"Evaluations of the serological test in the diagnosis of 2019 novel coronavirus (SARS-CoV-2) infections during the COVID-19 outbreak","volume":"39","author":"D Lin","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"5","key":"pcbi.1008728.ref003","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3390\/diagnostics10050319","article-title":"Antibody Tests in Detecting SARS-CoV-2 Infection: A Meta-Analysis","volume":"10","author":"PI Kontou","year":"2020","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"pcbi.1008728.ref004","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1038\/s41467-020-17317-y","article-title":"An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment","volume":"11","author":"CH GeurtsvanKessel","year":"2020","journal-title":"Nat Commun"},{"issue":"8","key":"pcbi.1008728.ref005","doi-asserted-by":"crossref","first-page":"e01243","DOI":"10.1128\/JCM.01243-20","article-title":"Performance Characteristics of Four High-Throughput Immunoassays for Detection of IgG Antibodies against SARS-CoV-2","volume":"58","author":"ES Theel","year":"2020","journal-title":"J Clin Microbiol"},{"key":"pcbi.1008728.ref006","doi-asserted-by":"crossref","first-page":"104394","DOI":"10.1016\/j.jcv.2020.104394","article-title":"Comparison of four new commercial serologic assays for determination of SARS-CoV-2 IgG","volume":"128","author":"A Kr\u00fcttgen","year":"2020","journal-title":"J Clin Virol"},{"key":"pcbi.1008728.ref007","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cca.2020.07.007","article-title":"Comparison of test performance of commercial anti-SARS-CoV-2 immunoassays in serum and plasma samples","volume":"510","author":"V Haselmann","year":"2020","journal-title":"Clin Chim Acta"},{"issue":"1","key":"pcbi.1008728.ref008","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/oxfordjournals.aje.a112510","article-title":"Estimating prevalence from the results of a screening test","volume":"107","author":"WJ Rogan","year":"1978","journal-title":"Am J Epidemiol. Oxford University Press"},{"issue":"6","key":"pcbi.1008728.ref009","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/ije\/25.6.1107","article-title":"Basic methods for sensitivity analysis of biases","volume":"25","author":"S Greenland","year":"1996","journal-title":"Int J Epidemiol"},{"key":"pcbi.1008728.ref010","article-title":"Estimating prevalence using an imperfect test","author":"PJ Diggle","year":"2011","journal-title":"Epidemiology Research International"},{"key":"pcbi.1008728.ref011","article-title":"Covid-19 antibody seroprevalence in santa clara county, california","author":"E Bendavid","year":"2020","journal-title":"MedRxiv"},{"issue":"3","key":"pcbi.1008728.ref012","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/oxfordjournals.aje.a117428","article-title":"Bayesian estimation of disease prevalence and the parameters of diagnostic tests in the absence of a gold standard","volume":"141","author":"L Joseph","year":"1995","journal-title":"Am J Epidemiol"},{"key":"pcbi.1008728.ref013","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/931542","article-title":"Bayesian Estimation of the True Prevalence and of the Diagnostic Test Sensitivity and Specificity of Enteropathogenic Yersinia in Finnish Pig Serum Samples","volume":"2015","author":"MJ Vilar","year":"2015","journal-title":"Biomed Res Int"},{"issue":"10247","key":"pcbi.1008728.ref014","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0140-6736(20)31304-0","article-title":"Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study","volume":"396","author":"S Stringhini","year":"2020","journal-title":"Lancet"},{"key":"pcbi.1008728.ref015","article-title":"Jointly modeling prevalence, sensitivity and specificity for optimal sample allocation","author":"DB Larremore","year":"2020","journal-title":"bioRxiv"},{"key":"pcbi.1008728.ref016","article-title":"Bayesian analysis of tests with unknown specificity and sensitivity","author":"A Gelman","year":"2020","journal-title":"medRxiv"},{"issue":"11","key":"pcbi.1008728.ref017","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1093\/aje\/kwr245","article-title":"Age-dependent patterns of infection and severity explaining the low impact of 2009 influenza A (H1N1): evidence from serial serological surveys in the Netherlands","volume":"174","author":"A Steens","year":"2011","journal-title":"Am J Epidemiol"},{"issue":"1","key":"pcbi.1008728.ref018","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1017\/S0950268812000404","article-title":"Time-course of antibody responses against Coxiella burnetii following acute Q fever","volume":"141","author":"PF Teunis","year":"2013","journal-title":"Epidemiol Infect"},{"issue":"11","key":"pcbi.1008728.ref019","doi-asserted-by":"crossref","first-page":"e113021","DOI":"10.1371\/journal.pone.0113021","article-title":"Discrimination of influenza infection (A\/2009 H1N1) from prior exposure by antibody protein microarray analysis","volume":"9","author":"DE Te Beest","year":"2014","journal-title":"PLoS One"},{"issue":"103","key":"pcbi.1008728.ref020","doi-asserted-by":"crossref","first-page":"20141244","DOI":"10.1098\/rsif.2014.1244","article-title":"Joint modelling of serological and hospitalization data reveals that high levels of pre-existing immunity and school holidays shaped the influenza A pandemic of 2009 in the Netherlands","volume":"12","author":"DE Te Beest","year":"2015","journal-title":"J R Soc Interface"},{"issue":"1","key":"pcbi.1008728.ref021","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/EDE.0000000000000196","article-title":"Estimating seroprevalence of human papillomavirus type 16 using a mixture model with smoothed age-dependent mixing proportions","volume":"26","author":"MA Vink","year":"2015","journal-title":"Epidemiology"},{"issue":"8","key":"pcbi.1008728.ref022","doi-asserted-by":"crossref","first-page":"e0161109","DOI":"10.1371\/journal.pone.0161109","article-title":"A Bivariate Mixture Model for Natural Antibody Levels to Human Papillomavirus Types 16 and 18: Baseline Estimates for Monitoring the Herd Effects of Immunization","volume":"11","author":"MA Vink","year":"2016","journal-title":"PLoS One"},{"issue":"9","key":"pcbi.1008728.ref023","doi-asserted-by":"crossref","first-page":"e1005719","DOI":"10.1371\/journal.pcbi.1005719","article-title":"Infectious reactivation of cytomegalovirus explaining age- and sex-specific patterns of seroprevalence","volume":"13","author":"M van Boven","year":"2017","journal-title":"PLoS Comput Biol"},{"key":"pcbi.1008728.ref024","article-title":"Evaluation of nine commercial SARS-CoV-2 immunoassays","author":"R Lassauni\u00e8re","year":"2020","journal-title":"medRxiv"},{"issue":"7","key":"pcbi.1008728.ref025","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.3201\/eid2607.200841","article-title":"Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients","volume":"26","author":"NMA Okba","year":"2020","journal-title":"Emerging Infect Dis"},{"issue":"10","key":"pcbi.1008728.ref026","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.cmi.2020.06.024","article-title":"Validation of a commercially available SARS-CoV-2 serological immunoassay","volume":"26","author":"B Meyer","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"pcbi.1008728.ref027","article-title":"The role of asymptomatic SARS-CoV-2 infections: rapid living systematic review and meta-analysis","author":"DC Buitrago-Garcia","year":"2020","journal-title":"medRxiv"},{"issue":"5","key":"pcbi.1008728.ref028","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/irv.12074","article-title":"H1N1pdm serology working group. Estimating age-specific cumulative incidence for the 2009 influenza pandemic: a meta-analysis of A(H1N1)pdm09 serological studies from 19 countries","volume":"7","author":"MD Van Kerkhove","year":"2013","journal-title":"Influenza Other Respir Viruses"},{"key":"pcbi.1008728.ref029","article-title":"Neutralizing and binding antibody kinetics of COVID-19 patients during hospital and convalescent phases","author":"X Yao","year":"2020","journal-title":"medRxiv"},{"key":"pcbi.1008728.ref030","article-title":"Estimating SARS-CoV-2 seroprevalence and epidemiological parameters with uncertainty from serological surveys","author":"DB Larremore","year":"2020","journal-title":"medRxiv"},{"key":"pcbi.1008728.ref031","volume-title":"Statistical methods in diagnostic medicine","author":"X Zhou","year":"2009"},{"key":"pcbi.1008728.ref032","article-title":"The statistical evaluation of medical tests for classification and prediction","author":"MS Pepe","year":"2003","journal-title":"Medicine"},{"issue":"1","key":"pcbi.1008728.ref033","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","article-title":"Index for rating diagnostic tests","volume":"3","author":"WJ Youden","year":"1950","journal-title":"Cancer"},{"key":"pcbi.1008728.ref034","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2020. URL: http:\/\/www.R-project.org\/."},{"key":"pcbi.1008728.ref035","unstructured":"Stan Development Team. RStan: the R interface to Stan 2020. URL: http:\/\/mc-stan.org\/."},{"key":"pcbi.1008728.ref036","doi-asserted-by":"crossref","DOI":"10.18637\/jss.v076.i01","article-title":"Stan: A probabilistic programming language","volume":"76","author":"B Carpenter","year":"2017","journal-title":"Journal of statistical software"}],"updated-by":[{"DOI":"10.1371\/journal.pcbi.1008728","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T00:00:00Z","timestamp":1615334400000}}],"container-title":["PLOS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1008728","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T13:56:16Z","timestamp":1615384576000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1008728"}},"subtitle":[],"editor":[{"given":"James","family":"Lloyd-Smith","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,2,26]]},"references-count":36,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1008728","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.04.29.068999","asserted-by":"object"}]},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,26]]}}}